Deutsche Bank Revists The Story on Teva Pharma (TEVA); Many Catalysts Ahead, Floor Established at $35

Deutsche Bank maintains a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $48.00.

Analyst, David M. Steinberg, said, "With several near term catalysts (Copaxone court decision, upcoming analyst meeting, etc.), we like Teva’s risk-reward profile at current levels. Moreover, Teva’s FCF yield is ~2x the average of both Major and Generic Pharma."

Steinberg sees approx. $10 of upside vs. $3/share downside, and that the stock being close to five year lows, it makes sense to revisit this story considering several upcoming catalysts.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $38.10 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Teva Pharma (TEVA) PT Raised to $42 at Barclays
• UBS Reiterates Buy Rating on HF Sinclair (DINO)
• Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential